TherapeuticsMD Stock Price, News & Analysis (NASDAQ:TXMD)

$5.58 +0.06 (+1.09 %)
(As of 02/18/2018 04:00 PM ET)
Previous Close$5.58
Today's Range$5.39 - $5.61
52-Week Range$3.50 - $8.30
Volume1.41 million shs
Average Volume1.79 million shs
Market Capitalization$1.21 billion
P/E Ratio-14.31
Dividend YieldN/A
Beta0.99

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:TXMD
CUSIPN/A
Phone+1-561-9611911

Debt

Debt-to-Equity RatioN/A
Current Ratio14.44%
Quick Ratio14.32%

Price-To-Earnings

Trailing P/E Ratio-14.3076923076923
Forward P/E Ratio-15.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.36 million
Price / Sales62.37
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book8.58

Profitability

Trailing EPS($0.39)
Net Income$-89,870,000.00
Net Margins-457.00%
Return on Equity-65.16%
Return on Assets-58.66%

Miscellaneous

Employees159
Outstanding Shares216,400,000

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Monday, November, 6th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. The company had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The company's quarterly revenue was down 19.7% compared to the same quarter last year. During the same period last year, the company earned ($0.13) earnings per share. View TherapeuticsMD's Earnings History.

Where is TherapeuticsMD's stock going? Where will TherapeuticsMD's stock price be in 2018?

9 brokers have issued 1-year target prices for TherapeuticsMD's shares. Their forecasts range from $6.00 to $28.00. On average, they expect TherapeuticsMD's stock price to reach $14.50 in the next year. View Analyst Ratings for TherapeuticsMD.

What are Wall Street analysts saying about TherapeuticsMD stock?

Here are some recent quotes from research analysts about TherapeuticsMD stock:

  • 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (1/20/2018)
  • 2. Jefferies Group LLC analysts commented, "TXMD and its expert speakers/consultants made convincing cases for TX-001 and '004 as differentiated and needed HRTs for VMS/VVA. With strong senior talent and sound marketing strategies, we believe '004 can take meaningful share (even without a clean label with no boxed safety warnings), while '001 can become the new standard of care, especially in the compounding pharmacy channel (with no competition). TXMD remains a top 2017 small-cap pick." (3/2/2017)

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in January. As of January 31st, there was short interest totalling 52,410,927 shares, an increase of 1.8% from the January 12th total of 53,373,083 shares. Based on an average trading volume of 1,716,615 shares, the days-to-cover ratio is currently 30.5 days. Currently, 30.1% of the shares of the company are sold short.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:

  • Tommy G. Thompson J.D., Independent Chairman of the Board (Age 75)
  • John C. K. Milligan IV, President, Secretary, Director (Age 54)
  • Robert G. Finizio, Chief Executive Officer, Director (Age 46)
  • Daniel A. Cartwright, Chief Financial Officer, Treasurer (Age 59)
  • Mitchell L. Krassan, Executive Vice President, Chief Strategy Officer (Age 51)
  • Michael Donegan, Vice President - Finance (Age 49)
  • Brian Bernick M.D., Chief Clinical Officer, Director (Age 48)
  • Jules A. Musing, Director (Age 69)
  • J. Martin Carroll, Independent Director (Age 68)
  • Cooper C. Collins, Independent Director (Age 38)

Who owns TherapeuticsMD stock?

TherapeuticsMD's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (13.39%), BlackRock Inc. (6.67%), Franklin Resources Inc. (5.08%), OppenheimerFunds Inc. (0.76%), Geode Capital Management LLC (0.74%) and Rock Springs Capital Management LP (0.54%). Company insiders that own TherapeuticsMD stock include Cooper C Collins and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.

Who sold TherapeuticsMD stock? Who is selling TherapeuticsMD stock?

TherapeuticsMD's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Rock Springs Capital Management LP, Teachers Advisors LLC, Candriam Luxembourg S.C.A., Metropolitan Life Insurance Co. NY, Rhumbline Advisers, Wells Fargo & Company MN and Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD.

Who bought TherapeuticsMD stock? Who is buying TherapeuticsMD stock?

TherapeuticsMD's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Ardsley Advisory Partners, Franklin Resources Inc., Nexthera Capital LP, Tekla Capital Management LLC, Geode Capital Management LLC and Deutsche Bank AG. Company insiders that have bought TherapeuticsMD stock in the last two years include Cooper C Collins and Tommy G Thompson. View Insider Buying and Selling for TherapeuticsMD.

How do I buy TherapeuticsMD stock?

Shares of TherapeuticsMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TherapeuticsMD stock can currently be purchased for approximately $5.58.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.21 billion and generates $19.36 million in revenue each year. The company earns $-89,870,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. TherapeuticsMD employs 159 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 Broken Sound Pkwy NW, BOCA RATON, FL 33487-2721, United States. The company can be reached via phone at +1-561-9611911 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (TXMD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TherapeuticsMD (NASDAQ:TXMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.913.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.50$14.50$14.72$17.39
Price Target Upside: 128.71% upside124.81% upside130.01% upside192.74% upside

TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History

Price Target History for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2018OppenheimerReiterated RatingBuy$10.00LowView Rating Details
1/7/2018Cantor FitzgeraldReiterated RatingBuy$28.00LowView Rating Details
12/29/2017Noble FinancialReiterated RatingBuyN/AView Rating Details
12/20/2017Deutsche BankSet Price TargetBuy$9.00HighView Rating Details
11/6/2017CowenReiterated RatingOutperform$13.00 -> $16.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$15.00MediumView Rating Details
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00N/AView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$20.00LowView Rating Details
7/11/2017CIBCUpgradeMarket Perform -> OutperformHighView Rating Details
12/6/2016GuggenheimReiterated RatingPositiveN/AView Rating Details
12/4/2016Goldman Sachs GroupReiterated RatingBuy$10.50N/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

TherapeuticsMD (NASDAQ:TXMD) Earnings History and Estimates Chart

Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ TXMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.10)($0.07)$5.36 million$4.42 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.11)($0.10)$4.91 million$4.25 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.11)($0.11)ViewN/AView Earnings Details
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)ViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.08)($0.07)ViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
11/4/2013Q3 2013($0.04)($0.06)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.06)($0.05)ViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.06)($0.05)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.04)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

TherapeuticsMD (NASDAQ:TXMD) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.37 EPS
Next Year EPS Consensus Estimate: $-0.42 EPS

Dividends

Dividend History for TherapeuticsMD (NASDAQ:TXMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.92%
Institutional Ownership Percentage: 72.65%
Insider Trades by Quarter for TherapeuticsMD (NASDAQ:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ TXMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2017Tommy G ThompsonDirectorBuy5,000$6.21$31,050.003,555View SEC Filing  
8/30/2017Tommy G ThompsonDirectorBuy5,000$5.99$29,950.003,555View SEC Filing  
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.0036,000View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.0048,500View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.0010,000View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60297,000View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.401,722,419View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.1021,029,533View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.006,318,018View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.0022,011,586View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.006,343,018View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TherapeuticsMD (NASDAQ TXMD) News Headlines

Source:
DateHeadline
TherapeuticsMD Inc (TXMD) to Post FY2018 Earnings of ($0.45) Per Share, Jefferies Group ForecastsTherapeuticsMD Inc (TXMD) to Post FY2018 Earnings of ($0.45) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - February 15 at 10:56 AM
Jefferies Group Weighs in on TherapeuticsMD Incs FY2020 Earnings (TXMD)Jefferies Group Weighs in on TherapeuticsMD Inc's FY2020 Earnings (TXMD)
www.americanbankingnews.com - February 14 at 3:34 PM
TherapeuticsMD (TXMD) Upgraded at BidaskClubTherapeuticsMD (TXMD) Upgraded at BidaskClub
www.americanbankingnews.com - February 11 at 6:22 AM
TherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20TherapeuticsMD to Host Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast on February 20
finance.yahoo.com - February 7 at 9:41 AM
TherapeuticsMD, Inc. (TXMD) Expected to Announce Quarterly Sales of $4.69 MillionTherapeuticsMD, Inc. (TXMD) Expected to Announce Quarterly Sales of $4.69 Million
www.americanbankingnews.com - February 7 at 3:44 AM
TherapeuticsMD, Inc. (TXMD) Expected to Post Earnings of -$0.09 Per ShareTherapeuticsMD, Inc. (TXMD) Expected to Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 5 at 9:10 PM
RSI Alert: TherapeuticsMD (TXMD) Now OversoldRSI Alert: TherapeuticsMD (TXMD) Now Oversold
www.nasdaq.com - February 2 at 3:49 PM
RSI Alert: TherapeuticsMD (TXMD) Now Oversold - NasdaqRSI Alert: TherapeuticsMD (TXMD) Now Oversold - Nasdaq
www.nasdaq.com - February 2 at 9:31 AM
TherapeuticsMD (TXMD) Cut to "Strong Sell" at BidaskClubTherapeuticsMD (TXMD) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - February 1 at 12:30 AM
TherapeuticsMD (TXMD) Rating Reiterated by OppenheimerTherapeuticsMD (TXMD) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - January 29 at 1:14 PM
TherapeuticsMD, Inc. (TXMD) Receives Average Rating of "Buy" from BrokeragesTherapeuticsMD, Inc. (TXMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 27 at 3:50 AM
TherapeuticsMD, Inc. (TXMD) Sees Large Drop in Short InterestTherapeuticsMD, Inc. (TXMD) Sees Large Drop in Short Interest
www.americanbankingnews.com - January 27 at 2:10 AM
 Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Post Quarterly Sales of $4.69 Million Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Post Quarterly Sales of $4.69 Million
www.americanbankingnews.com - January 22 at 1:56 PM
TherapeuticsMD (TXMD) Stock Rating Upgraded by Zacks Investment ResearchTherapeuticsMD (TXMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 20 at 9:40 PM
TherapeuticsMD (TXMD) Downgraded by Zacks Investment Research to SellTherapeuticsMD (TXMD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - January 12 at 8:12 PM
TherapeuticsMD, Inc. (TXMD) Sees Significant Growth in Short InterestTherapeuticsMD, Inc. (TXMD) Sees Significant Growth in Short Interest
www.americanbankingnews.com - January 12 at 3:48 AM
TherapeuticsMD (TXMD) Stock Rating Reaffirmed by Cantor FitzgeraldTherapeuticsMD (TXMD) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - January 8 at 1:38 PM
TherapeuticsMD Announces Presentation at 36th Annual JP Morgan Healthcare Conference on January 10 - Business Wire (press release)TherapeuticsMD Announces Presentation at 36th Annual JP Morgan Healthcare Conference on January 10 - Business Wire (press release)
www.businesswire.com - January 4 at 8:02 AM
TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10TherapeuticsMD Announces Presentation at 36th Annual J.P. Morgan Healthcare Conference on January 10
finance.yahoo.com - January 3 at 4:34 PM
TherapeuticsMD, Inc. (TXMD) Given Consensus Rating of "Buy" by BrokeragesTherapeuticsMD, Inc. (TXMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 2 at 4:22 AM
TherapeuticsMD (TXMD) Earns "Buy" Rating from Noble FinancialTherapeuticsMD (TXMD) Earns "Buy" Rating from Noble Financial
www.americanbankingnews.com - December 30 at 10:34 AM
Short Interest in TherapeuticsMD, Inc. (TXMD) Declines By 3.0%Short Interest in TherapeuticsMD, Inc. (TXMD) Declines By 3.0%
www.americanbankingnews.com - December 30 at 2:00 AM
TherapeuticsMDs (TXMD) Buy Rating Reaffirmed at Cantor FitzgeraldTherapeuticsMD's (TXMD) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 29 at 1:26 PM
After-Hours Movers 12/28: (UCTT) (TXMD) (SD) Higher; (BCEI) Lower (more...)After-Hours Movers 12/28: (UCTT) (TXMD) (SD) Higher; (BCEI) Lower (more...)
www.streetinsider.com - December 29 at 9:26 AM
TherapeuticsMD Submits NDA for VMS Candidate, Shares RiseTherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
www.zacks.com - December 29 at 9:26 AM
TherapeuticsMD (TXMD) Submits TX-001HR NDA - StreetInsider.com - StreetInsider.comTherapeuticsMD (TXMD) Submits TX-001HR NDA - StreetInsider.com - StreetInsider.com
www.streetinsider.com - December 29 at 5:16 AM
TherapeuticsMD Announces Submission of New Drug Application for TX-001HRTherapeuticsMD Announces Submission of New Drug Application for TX-001HR
finance.yahoo.com - December 29 at 5:16 AM
ETFs with exposure to TherapeuticsMD, Inc. : December 26, 2017ETFs with exposure to TherapeuticsMD, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:46 PM
TherapeuticsMD: Class 2 Re-Submission Is Not The End Of The World - Seeking AlphaTherapeuticsMD: Class 2 Re-Submission Is Not The End Of The World - Seeking Alpha
seekingalpha.com - December 26 at 11:45 AM
TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017TherapeuticsMD, Inc. :TXMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:02 PM
TherapeuticsMD, Inc. (TXMD) to Post FY2018 Earnings of ($0.40) Per Share, Jefferies Group ForecastsTherapeuticsMD, Inc. (TXMD) to Post FY2018 Earnings of ($0.40) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - December 25 at 9:08 AM
Equities Analysts Issue Forecasts for TherapeuticsMD, Inc.s FY2018 Earnings (TXMD)Equities Analysts Issue Forecasts for TherapeuticsMD, Inc.'s FY2018 Earnings (TXMD)
www.americanbankingnews.com - December 25 at 9:08 AM
TherapeuticsMD (TXMD) Lowered to "Strong Sell" at BidaskClubTherapeuticsMD (TXMD) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - December 23 at 12:16 AM
FY2018 EPS Estimates for TherapeuticsMD, Inc. Increased by Cantor Fitzgerald (TXMD)FY2018 EPS Estimates for TherapeuticsMD, Inc. Increased by Cantor Fitzgerald (TXMD)
www.americanbankingnews.com - December 22 at 3:26 PM
3 Strong Buy Biotechs That Can Double in 20183 'Strong Buy' Biotechs That Can Double in 2018
www.nasdaq.com - December 21 at 10:23 AM
TherapeuticsMD (TXMD) PT Set at $10.00 by OppenheimerTherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer
www.americanbankingnews.com - December 21 at 8:44 AM
Deutsche Bank Analysts Give TherapeuticsMD (TXMD) a $9.00 Price TargetDeutsche Bank Analysts Give TherapeuticsMD (TXMD) a $9.00 Price Target
www.americanbankingnews.com - December 20 at 5:14 PM
Pre-Open Movers 12/20: (NETE) (NXTD) (SSC) Higher; (SFIX) (SCS) (TXMD) Lower (more...)Pre-Open Movers 12/20: (NETE) (NXTD) (SSC) Higher; (SFIX) (SCS) (TXMD) Lower (more...)
www.streetinsider.com - December 20 at 11:01 AM
TherapeuticsMD Falls Despite Acceptance of NDA: Here's WhyTherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
finance.yahoo.com - December 20 at 10:47 AM
TherapeuticsMD Falls Despite Acceptance of NDA: Heres WhyTherapeuticsMD Falls Despite Acceptance of NDA: Here's Why
www.zacks.com - December 20 at 10:27 AM
TherapeuticsMD shares drop 7% on new FDA review timeline for its drugTherapeuticsMD shares drop 7% on new FDA review timeline for its drug
finance.yahoo.com - December 20 at 10:24 AM
TherapeuticsMD (TXMD) Reports FDA Acceptance of New Drug ... - StreetInsider.comTherapeuticsMD (TXMD) Reports FDA Acceptance of New Drug ... - StreetInsider.com
www.streetinsider.com - December 20 at 7:47 AM
TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HRTherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
finance.yahoo.com - December 20 at 7:47 AM
 Brokerages Anticipate TherapeuticsMD, Inc. (TXMD) Will Announce Quarterly Sales of $4.69 Million Brokerages Anticipate TherapeuticsMD, Inc. (TXMD) Will Announce Quarterly Sales of $4.69 Million
www.americanbankingnews.com - December 19 at 9:10 AM
DARA Biosciences (DARA) and TherapeuticsMD (TXMD) Head to Head SurveyDARA Biosciences (DARA) and TherapeuticsMD (TXMD) Head to Head Survey
www.americanbankingnews.com - December 18 at 9:34 AM
Traders Purchase High Volume of Put Options on TherapeuticsMD (TXMD)Traders Purchase High Volume of Put Options on TherapeuticsMD (TXMD)
www.americanbankingnews.com - December 18 at 3:10 AM
Zacks: Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Announce Earnings of -$0.09 Per ShareZacks: Analysts Expect TherapeuticsMD, Inc. (TXMD) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - December 17 at 1:26 PM
Short Interest in TherapeuticsMD, Inc. (TXMD) Decreases By 2.8%Short Interest in TherapeuticsMD, Inc. (TXMD) Decreases By 2.8%
www.americanbankingnews.com - December 14 at 4:10 AM
TherapeuticsMD (TXMD) Rating Increased to Sell at BidaskClubTherapeuticsMD (TXMD) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - December 12 at 5:20 PM
TherapeuticsMD, Inc. (TXMD) Director Purchases $31,050.00 in StockTherapeuticsMD, Inc. (TXMD) Director Purchases $31,050.00 in Stock
www.americanbankingnews.com - December 11 at 6:30 PM

SEC Filings

TherapeuticsMD (NASDAQ:TXMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TherapeuticsMD (NASDAQ TXMD) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.